A new study shows that people Zepbound lost about 50% more weight than those using Wegovy.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

U.S. stocks ripped higher after an encouraging update on U.S. inflation.

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.

Cornelius Eady, Toi Derricotte and Kimiko Hahn are among this year’s winners of awards from the Poetry Foundation, which announced some of poetry's most lucrative prizes.

Eli Lilly will cap the out-of-pocket cost of its insulin at $35 a month, the drugmaker said Wednesday. The move, experts say, could prompt other insulin makers in the U.S. to follow suit.

FILE - This is an April 26, 2017, file photo showing Eli Lilly corporate headquarters in Indianapolis. Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday, Oct. 27, 2020, that It remains confident that its drug may stop COVID from developing in other patients. (AP Photo/Darron Cummings, File)HOUSTON – Eli Lilly’s announced Tuesday the approval by the U.S. Food and Drug Administration (FDA) of Emergency Use Authorization (EUA) for its combination antibody therapy. Lilly will collaborate with the bio-tech company Amgen to manufacture up to one million doses of etesevimab for administration with bamlanivimab by mid-2021.

(Eli Lilly via AP)New results extend hopes for drugs that supply antibodies to fight COVID-19, suggesting they can help keep patients out of the hospital and possibly prevent illness in some uninfected people. Separately, Regeneron Pharmaceuticals Inc. said partial results from an ongoing study suggest its drug combo completely prevented symptomatic infections in housemates of someone with COVID-19. The need for an infusion has greatly limited the use of antibody drugs in the pandemic because of health care shortages. U.S. regulators have allowed emergency use of some Lilly and Regeneron antibodies for mild or moderate COVID-19 cases that do not require hospitalization while studies of them continued. Lilly’s new results were from a study of 1,035 non-hospitalized patients recently diagnosed with COVID-19.

FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from these drugs, which supply antibodies to help the immune system fight the coronavirus. Ironically, government advisers met Wednesday and Thursday to plan for the opposite problem: potential future shortages of the drug as COVID-19 cases continue to rise. The drugs aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. Eli Lilly and Regeneron Pharmaceuticals have emergency authorization to supply their antibody drugs while studies continue.

On Monday, Nov. 9, 2020, the Food and Drug Administration cleared emergency use of Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. The drug is for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. The Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. Regeneron Pharmaceuticals Inc. also has asked for emergency authorization for an antibody drug it is testing, the one Trump received. FDA regulators authorized the Lilly drug using their emergency powers to quickly speed the availability of experimental drugs and other medical products during public health crises.

People wearing face masks walk past a bank's electronic board showing the Hong Kong share index in Hong Kong, Wednesday, Oct. 28, 2020. Asian shares headed lower Wednesday on worries about rising virus counts and Washington's inability to deliver more aid to the economy. (AP Photo/Kin Cheung)Asian shares headed lower Wednesday on worries about rising virus counts and Washington's inability to deliver more aid to the economy. Japan's benchmark Nikkei 225 fell 0.3% in morning trading to 23,420.93, while South Korea's Kospi declined 0.2% to 2,325.22. The U.S. dollar weakened to 104.30 Japanese yen from 104.41 yen late Tuesday.

U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue. In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. The company also is continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera. Lilly and Regeneron have asked the U.S. Food and Drug Administration to grant emergency use authorization for their drugs for COVID-19 while late-stage studies continue.

The paused study, called ACTIV-3, started in August and aims to enroll 10,000 hospitalized COVID-19 patients in the United States, Denmark and Singapore. The pause in the Lilly study comes a day after a temporary halt to enrollment in a coronavirus vaccine study. Johnson & Johnson executives said Tuesday that it will be a few days before they know more about an unexplained illness in one participant that caused a pause in its late-stage vaccine study. Johnson & Johnson isn’t disclosing the nature of the illness. He says Johnson & Johnson gave information on the case to the independent monitoring board overseeing the safety of patients in the study, as the research protocol requires.

A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled Hispanics and Blacks. The drug, given through an IV, tamps down a protein called interleukin-6 that’s often found in excess in COVID-19 patients. About 12% given the drug needed a breathing machine or died within 28 days versus about 19% of patients given a placebo. This is the third time this week that companies have announced positive results from studies testing COVID treatments via press releases. On Monday, Eli Lilly reported benefits from a study testing its anti-inflammatory drug baricitinib when combined with the antiviral drug remdesivir.

A drug company says that partial results from a study testing an antibody drug give hints that it may help mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet. He had no role in the Lilly study but helps direct antibody studies for a public-private research group the federal government formed to speed testing of these drugs. The study will continue to test the antibody drug in combination with another from a Chinese company, Junshi Biosciences. Lilly has already started manufacturing its antibody drug, hoping to have hundreds of thousands of doses ready by fall if studies give positive results. Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing a two-antibody drug for coronavirus.

A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. All study participants received remdesivir, a Gilead Sciences drug previously shown to reduce the time to recovery, defined as being well enough to leave the hospital, by four days on average. Those who also were given baricitinib recovered one day sooner than those given remdesivir alone, Lilly said. Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized COVID-19 patients.

The antibody drugs are very promising and, in contrast, could be available fairly soon," said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results. Another company that developed an antibody drug cocktail against Ebola Regeneron Pharmaceuticals Inc. now is testing one for coronavirus. Others working on antibody drugs include Amgen and Adaptive Biotechnologies. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever theyre needed.

A vaccine to protect us against coronavirus may be a year or more away but there are other technologies on the horizon that could help protect people from getting the virus. You've heard a lot about antibody treatments when we talk about convalescent plasma. Some of our local hospitals are using blood plasma from survivors to help sick patients make a recovery. Regeneron and Eli Lilly are among American favorites to develop antibody treatments. Those antibody treatments, they say, could be ready by the end of this year.